-+ 0.00%
-+ 0.00%
-+ 0.00%

Tenaya Therapeutics Announces Late Breaker Presentation Of New Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 At American College Of Cardiology Annual Meeting

Benzinga·03/31/2025 14:06:40
Listen to the news

TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose

New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time

All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I

Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy

Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report Initial Data in 2H25